Literature DB >> 32567239

Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.

Alexander A Iyer1, Saskia Hendriks2, Annette Rid2.   

Abstract

As hospitals have experienced a surge of Covid-19 patients, investigators of Covid-19 treatment trials face a difficult problem: when an institution has more eligible and interested patients than trial slots, who should be enrolled? Defining a clear strategy for selecting participants for "high-demand" Covid-19 treatment trials is important to avoid ad hoc and potentially biased decision-making by local investigators, which could inadvertently compromise a trial's social value, participants' interests, or fairness. In this article, we propose a set of ethical criteria for evaluating participant-selection strategies for such trials. We argue that the pandemic context-in particular, great urgency to develop safe and effective treatments, uncertainty surrounding Covid-19, and strain on the health care system that limits the time and effort available for trial enrollment-favors participant-selection strategies that optimize the ease of enrollment and, ideally, social value. A lottery and, where possible, a weighted lottery have important advantages in these respects. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Covid-19; clinical trials; fair participant selection; human subjects research; lottery; research ethics

Year:  2020        PMID: 32567239     DOI: 10.1002/eahr.500061

Source DB:  PubMed          Journal:  Ethics Hum Res        ISSN: 2578-2355


  3 in total

1.  Allocation of Opportunities to Participate in Clinical Trials during the Covid-19 Pandemic and Other Public Health Emergencies.

Authors:  Kayte Spector-Bagdady; Holly Fernandez Lynch; Barbara E Bierer; Luke Gelinas; Sara Chandros Hull; David Magnus; Michelle N Meyer; Richard R Sharp; Jeremy Sugarman; Benjamin S Wilfond; Ruqaiijah Yearby; Seema Mohapatra
Journal:  Hastings Cent Rep       Date:  2021-12-15       Impact factor: 4.298

Review 2.  Ethical challenges for a new generation of early-phase pediatric gene therapy trials.

Authors:  Alexander A Iyer; Dimah Saade; Diana Bharucha-Goebel; A Reghan Foley; Gilberto 'Mike' Averion; Eduardo Paredes; Steven Gray; Carsten G Bönnemann; Christine Grady; Saskia Hendriks; Annette Rid
Journal:  Genet Med       Date:  2021-07-07       Impact factor: 8.822

3.  Ethical, regulatory, and practical barriers to COVID-19 research: A stakeholder-informed inventory of concerns.

Authors:  Bryan A Sisk; Kari Baldwin; Meredith Parsons; James M DuBois
Journal:  PLoS One       Date:  2022-03-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.